Antineoplastic Agents: Cytotoxic Agents: Mitotic Inhibitors
IVINB2 “Vinblastine injection” 1 mg/ml; 1 ml/vial
適應症：急性白血病、淋巴肉瘤、何杰金氏病。
Usual dose:
Adult: IV only, through the tubing of a running IV infusion or directly into vein over 1 min.
Usual dose: initial, 3.7 mg/m2, increase weekly till Max. 18.5 mg/m2, or WBC dropped to 3000/mm3.
Histiocytosis X: monotherapy, 6.5 mg/m2.
Hodgkings disease, in combination: 6 mg/m2.
Testicular germ cell carcinoma, in combination: 3 mg/m2.
Pediatric
Choriocarcinoma, Unresponsive to other chemotherapeutic agents: 3 mg/m2 when used in combination chemotherapy regimens; dose modifications should be guided by hematologic tolerance.
Hodgkin’s disease, Stages III and IV: 6 mg/m2 IV in combination with other agents.
Langerhans cell histiocytosis: initial dose, 6.5 mg/m(2) IV as a single agent.
Dose adjustment:
Hepatic impairment: direct serum bilirubin greater than 3 mg/100 mL, 50% dose reduction.
Renal impairment: no dosage modification is recommended.
Adverse effect:
Common: hypertension, alopecia, constipation, bone pain, jaw pain, malaise.
Serious: leukopenia, thrombocytopenia, cerebrovascular accident, neurotoxicity, acute respiratory distress syndrome, intrathecal administration.